Login to Your Account

Cellworks Taps Semiconductor Expertise to Boost Predictability

By Trista Morrison
Staff Writer

Wednesday, May 11, 2011

With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks Group Inc. is advancing lead drug CWG952 toward the clinic for rheumatoid arthritis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription